DOI: 10.4103/ijpam.ijpam_82_26 ISSN: 2352-6467

Patient-reported outcomes and glycemic control in individuals with type 1 diabetes started on a tubeless micropump system

Asma Deeb, Aqeel A. Farooq, Mohamed Al Sofiani, Hussein El Badawi
Show PDF Cite

Context

Patch pumps are tubeless insulin delivery systems that may improve treatment satisfaction and glycemic control in people with diabetes. However, real-world data on their use remains limited. Aims: To examine the real-world impact of transition from multiple daily injections (MDIs) to the Accu-Chek Solo micropump system on quality of life (QoL), patient-reported outcomes, and glycemic control in individuals with type 1 diabetes.

Settings and Design

Prospective, multicenter observational study.

Methods and Materials

Twelve individuals with type 1 diabetes transitioned from MDIs to the Accu-Chek Solo micropump system. Continuous glucose monitoring data were collected at baseline and monthly for 3 months. QoL and patient-reported outcomes were assessed using an adapted Diabetes Technology Questionnaire.

Statistical Analysis Used

Differences in QoL scores were compared with paired t -tests, while changes in glucometrics over time were assessed with repeated measures analysis of variance (ANOVA) with Tukey’s post hoc test.

Results

Transitioning to the Solo micropump led to significant improvements in glycemic outcomes, with mean glucose decreasing from 212 to 169 mg/dL ( P  = 0.007), GMI from 7.65% to 7.26% ( P  = 0.006), time in range increasing from 49.1% to 66.1% ( P  = 0.001), and time above range decreasing from 43.5% to 31.1% ( P  = 0.001). QoL scores improved from 44.9 ± 20.6 to 68.5 ± 20.0 ( P  = 0.022), and most participants reported multiple perceived benefits, including reduced fear of hypoglycemia and improved lifestyle flexibility.

Conclusions

Transitioning to the Solo patch pump improved QoL and short-term glycemic outcomes, supporting its use in selected individuals.

More from our Archive